Formulation Stability Patents: Top Companies & Filing Trends 2026
Formulation stability and degradation pathway patents: who holds the claim space and where it thins out
Concentrated at the top. The five leading assignees together hold 56.1% of all 396 records in scope, and the top ten reach 75.5%. Annual filings rose from 42 in 2017 to a peak of 55 in 2021, then fell to 15 by 2024 — a 73% drop over that three-year window. Because publication lags filing by roughly 18 months, the low counts recorded for 2025 and 2026 reflect the reporting gap as much as any change in filing behaviour, and should not be read as the field going quiet.
- 1MEDIMMUNE LLC75
- 2ASTRAZENECA AB60
- 3EISAI R&D MANAGEMENT CO LTD38
- 4GLEKSOSMITKLAJN INTPROP MANAGEMENT LTD30
- 5REGENERON PHARMACEUTICALS INC19
See the full formulation stability and degradation pathways analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who holds the most patents on formulation stability and degradation pathways?
One assignee leads the ranked list with 75 records, well ahead of the fifth-place company at 19 and tenth place at 13. The top five assignees combined hold 56.1% of all 396 records in scope, and the top ten reach 75.5%, so the field is concentrated but not a single-company monopoly. Behind that leading group sits a long tail of 72 further ranked companies, most with only a handful of filings each, which is where smaller developers and academic assignees tend to appear.
Is patent filing in this area still growing?
No, not on the complete-year data available. Filings peaked at 55 in 2021 and had fallen to 15 by 2024, a 73% decline over that span. The lower counts shown for 2025 and 2026 are not a reliable extension of that trend because publication lags filing by roughly 18 months, so those years are still filling in and should be re-checked later rather than read as a further collapse.
What patent classes dominate formulation stability filings?
A61K (medicinal preparations) and C07K (peptides and proteins) dominate, appearing on 76.8% and 73.7% of the 396 records respectively, which confirms this is primarily a biologics rather than small-molecule landscape. Secondary classes include A61P (therapeutic activity, 15.4%), C12P (fermentation and enzymatic synthesis, 12.1%) and G01N (material analysis and testing, 10.6%). Because a single record can carry multiple classes, these shares add up to more than 100% and should not be summed.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Formulation Stability and Degradation Pathways covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.